Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus : Are they different entities?
Copyright © 2018. Published by Elsevier B.V..
Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 17(2018), 8 vom: 15. Aug., Seite 739-745 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Belizna, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Antiphospholipid |
|---|
| Anmerkungen: |
Date Completed 22.08.2018 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2018.01.027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM285301608 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM285301608 | ||
| 003 | DE-627 | ||
| 005 | 20231225045137.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2018.01.027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0951.xml |
| 035 | |a (DE-627)NLM285301608 | ||
| 035 | |a (NLM)29885541 | ||
| 035 | |a (PII)S1568-9972(18)30138-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Belizna, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus |b Are they different entities? |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.08.2018 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018. Published by Elsevier B.V. | ||
| 520 | |a Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antiphospholipid syndrome | |
| 650 | 4 | |a Primary antiphospholipid syndrome | |
| 650 | 4 | |a Secondary antiphospholipid syndrome | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 700 | 1 | |a Stojanovich, Ljudmila |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Tervaert, Jan Willem |e verfasserin |4 aut | |
| 700 | 1 | |a Fassot, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Henrion, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Loufrani, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Gyorgy |e verfasserin |4 aut | |
| 700 | 1 | |a Muchardt, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Milena |e verfasserin |4 aut | |
| 700 | 1 | |a Ungeheuer, Marie Noelle |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaud, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Alijotas-Reig, Jaume |e verfasserin |4 aut | |
| 700 | 1 | |a Esteve-Valverde, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Nicoletti, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Saulnier, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Godon, Alban |e verfasserin |4 aut | |
| 700 | 1 | |a Reynier, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Chrétien, Jean Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Damian, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Omarjee, Loukman |e verfasserin |4 aut | |
| 700 | 1 | |a Mahé, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Pistorius, Marc Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Meroni, Pier Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Devreese, Katrien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 17(2018), 8 vom: 15. Aug., Seite 739-745 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2018 |g number:8 |g day:15 |g month:08 |g pages:739-745 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2018.01.027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2018 |e 8 |b 15 |c 08 |h 739-745 | ||